United States Biotechnology & Medical Research

Sarepta Therapeutics Inc (SRPT)

Track

The most recent insider trading activity at Sarepta Therapeutics Inc occurred on March 12, 2026, involving a sale of shares by Director Stephen Mayo. Prior to this, the company saw additional sales by executives in December 2025. There have been no reported insider transactions within the last three months.
Ticker: SRPT Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Sarepta Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 12 Mar 2026
Value US$1,329,161.14 | Price 409.64 | Shares 30,114 (-19.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-13 2026-03-12 S Sale
2.2
Mayo Stephen
Non-Executive Director
30,114 -19.6%
409.64
US$1,329,161 		30,114 -19.6% 409.64 US$1,329,161
2026-03-12 2026-03-12 PrS Proposed sale
2.2
STEPHEN MAYO

Director

Non-Executive Director
18,782
256.71
US$3,555,029 		18,782 256.71 US$3,555,029
2025-12-18 2025-12-16 S Sale
3.5
Estepan Ian Michael

Chief Operating Officer

Officer
13,586 +21.6%
53.15
US$4,294,057 		13,586 +21.6% 53.15 US$4,294,057
2025-12-16 2025-12-16 PrS Proposed sale
3.5
IAN M ESTEPAN

Officer

Officer
13,187
22.31
US$294,145 		13,187 22.31 US$294,145
2025-03-13 2025-03-12 S Sale
3.4
Nicaise Claude
Non-Executive Director
2,491 -8.2%
99.64
US$248,203 		2,491 -8.2% 99.64 US$248,203
2025-03-12 2025-03-12 PrS Proposed sale
3.4
Nicaise Claude

Director

Non-Executive Director
2,491
99.65
US$248,226 		2,491 99.65 US$248,226
2024-12-16 2024-12-12 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
10,500 -31.5%
124.84
US$1,310,820 		10,500 -31.5% 124.84 US$1,310,820
2024-12-12 2024-12-12 PrS Proposed sale
3.6
Wigzell Hans Lennart Rudolf

Director

Non-Executive Director
10,500
124.80
US$1,310,400 		10,500 124.80 US$1,310,400
2024-12-06 2024-12-05 S Sale
2.7
Boor Kathryn Jean
Non-Executive Director
1,636 -21.8%
125.55
US$205,400 		1,636 -21.8% 125.55 US$205,400
2024-12-05 2024-12-05 PrS Proposed sale
2.7
Boor Kathryn Jean

Director

Non-Executive Director
1,636
125.55
US$205,400 		1,636 125.55 US$205,400
2024-09-03 2024-08-30 S Sale
3.5
Estepan Ian Michael

Chief Financial Officer

Officer
5,985 -15.0%
137.36
US$822,100 		5,985 -15.0% 137.36 US$822,100
2024-08-30 2024-08-30 PrS Proposed sale
3.5
Estepan Ian Michael

Officer

Officer
5,985
137.37
US$822,130 		5,985 137.37 US$822,130
2024-08-20 2024-08-16 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
5,648 +2.0%
134.66
US$760,560 		5,648 +2.0% 134.66 US$760,560
2024-08-20 2024-08-16 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
18,284 +7.0%
134.06
US$2,451,153 		18,284 +7.0% 134.06 US$2,451,153
2024-08-20 2024-08-16 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
13,106 +5.3%
133.07
US$1,744,015 		13,106 +5.3% 133.07 US$1,744,015
2024-06-25 2024-06-25 PrS Proposed sale
2.0
BILAL ARIF

Officer

Officer
3,898
163.85
US$638,687 		3,898 163.85 US$638,687
2024-06-25 2024-06-25 PrS Proposed sale
1.4
RYAN BROWN

Officer

Officer
38,957
163.85
US$6,383,104 		38,957 163.85 US$6,383,104
2024-06-25 2024-06-25 PlS Planned sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
2,549 -13.0%
164.52
US$419,361 		2,549 -13.0% 164.52 US$419,361
2024-06-25 2024-06-25 PlS Planned sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
3,840 -16.3%
163.53
US$627,955 		3,840 -16.3% 163.53 US$627,955
2024-06-25 2024-06-25 PlS Planned sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
17,581 -42.8%
162.65
US$2,859,550 		17,581 -42.8% 162.65 US$2,859,550
2024-06-25 2024-06-25 PlS Planned sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
4,168 -9.2%
161.82
US$674,466 		4,168 -9.2% 161.82 US$674,466
2024-06-25 2024-06-25 PlS Planned sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
975 -2.1%
160.31
US$156,302 		975 -2.1% 160.31 US$156,302
2024-06-25 2024-06-25 PlS Planned sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
2,200 -4.5%
159.14
US$350,108 		2,200 -4.5% 159.14 US$350,108
2024-06-25 2024-06-25 PlS Planned sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
7,644 -13.6%
158.07
US$1,208,287 		7,644 -13.6% 158.07 US$1,208,287
2024-06-25 2024-06-25 PlS Planned sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
3,898 -18.3%
163.23
US$636,271 		3,898 -18.3% 163.23 US$636,271
2024-06-25 2024-06-24 PlS Planned sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
224 -1.0%
167.13
US$37,437 		224 -1.0% 167.13 US$37,437
2024-06-25 2024-06-24 PlS Planned sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
700 -3.2%
166.10
US$116,270 		700 -3.2% 166.10 US$116,270
2024-06-25 2024-06-24 PlS Planned sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
300 -1.3%
164.61
US$49,383 		300 -1.3% 164.61 US$49,383
2024-06-25 2024-06-24 PlS Planned sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
1,055 -4.5%
163.83
US$172,841 		1,055 -4.5% 163.83 US$172,841
2024-06-25 2024-06-24 PlS Planned sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
5,580 -19.2%
162.31
US$905,690 		5,580 -19.2% 162.31 US$905,690
2024-06-24 2024-06-24 PrS Proposed sale
2.0
BILAL ARIF

Officer

Officer
7,859
160.72
US$1,263,098 		7,859 160.72 US$1,263,098
2024-05-06 2024-05-02 PlS Planned sale
Murray Dallan

Chief Customer Officer

Officer
3,635 -16.7%
140.00
US$508,900 		3,635 -16.7% 140.00 US$508,900
2024-03-11 2024-03-11 PrS Proposed sale
2.7
Boor Kathryn Jean

Director

Non-Executive Director
761
122.93
US$93,547 		761 122.93 US$93,547
2024-03-11 2024-03-11 S Sale
2.7
Boor Kathryn Jean
Non-Executive Director
761 -9.2%
122.93
US$93,550 		761 -9.2% 122.93 US$93,550
2024-03-11 2024-03-08 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
100 -0.4%
122.39
US$12,239 		100 -0.4% 122.39 US$12,239
2024-03-11 2024-03-08 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
11,745 -33.9%
123.10
US$1,445,810 		11,745 -33.9% 123.10 US$1,445,810
2024-03-11 2024-03-08 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
3,155 -8.3%
123.85
US$390,747 		3,155 -8.3% 123.85 US$390,747
2024-03-08 2024-03-08 PrS Proposed sale
3.6
Wigzell Hans Lennart Rudolf

Director

Non-Executive Director
15,000
128.67
US$1,930,050 		15,000 128.67 US$1,930,050
2024-03-06 2024-03-05 S Sale
2.2
Mayo Stephen
Non-Executive Director
3,135 -32.1%
122.96
US$385,480 		3,135 -32.1% 122.96 US$385,480
2024-03-05 2024-03-05 PrS Proposed sale
2.2
Mayo Stephen

Director

Non-Executive Director
3,135
122.96
US$385,482 		3,135 122.96 US$385,482
2024-03-05 2024-03-01 S Sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
457 -1.7%
129.71
US$59,277 		457 -1.7% 129.71 US$59,277
2024-03-05 2024-03-01 S Sale
2.0
Arif Bilal

Chief Tech Ops Officer

Officer
1,543 -5.4%
128.58
US$198,399 		1,543 -5.4% 128.58 US$198,399
2024-03-05 2024-03-01 S Sale
1.4
Brown Ryan Edward

EVP, General Counsel

Officer
2,000 -5.9%
125.34
US$250,680 		2,000 -5.9% 125.34 US$250,680
2024-03-05 2024-03-01 S Sale
3.5
Estepan Ian Michael

Chief Financial Officer

Officer
1,200 -3.0%
128.30
US$153,960 		1,200 -3.0% 128.30 US$153,960
2024-03-01 2024-03-01 PrS Proposed sale
1.4
Brown Ryan Edward

Officer

Officer
2,269
125.44
US$284,635 		2,269 125.44 US$284,635
2024-03-01 2024-03-01 PrS Proposed sale
3.5
Estepan Ian Michael

Officer

Officer
1,565
127.81
US$200,020 		1,565 127.81 US$200,020
2024-03-01 2024-03-01 PrS Proposed sale
2.0
BILAL ARIF

Officer

Officer
2,000
128.83
US$257,670 		2,000 128.83 US$257,670
2023-11-06 2023-11-03 B Purchase
3.5
INGRAM DOUGLAS S

President & CEO

Executive Director
200 +0.1%
81.26
US$16,252 		200 +0.1% 81.26 US$16,252
2023-11-06 2023-11-03 B Purchase
3.5
INGRAM DOUGLAS S

President & CEO

Executive Director
3,884 +1.0%
80.33
US$312,002 		3,884 +1.0% 80.33 US$312,002
2023-11-06 2023-11-03 B Purchase
3.5
INGRAM DOUGLAS S

President & CEO

Executive Director
11,060 +2.9%
79.70
US$881,482 		11,060 +2.9% 79.70 US$881,482
2023-11-06 2023-11-03 B Purchase
3.5
INGRAM DOUGLAS S

President & CEO

Executive Director
10,081 +2.8%
78.57
US$792,064 		10,081 +2.8% 78.57 US$792,064
2023-11-06 2023-11-03 B Purchase
3.2
Barry Richard
Non-Executive Director
40,000 +40.0%
78.81
US$3,152,400 		40,000 +40.0% 78.81 US$3,152,400
2023-11-06 2023-11-03 B Purchase
3.2
Barry Richard
Non-Executive Director
10,000 +inf%
78.81
US$788,100 		10,000 +inf% 78.81 US$788,100
2023-08-15 2023-08-14 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
4,032 +1.7%
109.89
US$443,076 		4,032 +1.7% 109.89 US$443,076
2023-08-15 2023-08-14 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
5,947 +2.5%
109.19
US$649,353 		5,947 +2.5% 109.19 US$649,353
2023-08-14 2023-08-11 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
23,686 +11.1%
108.05
US$2,559,272 		23,686 +11.1% 108.05 US$2,559,272
2023-08-11 2023-08-10 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
31,570 +17.4%
106.26
US$3,354,628 		31,570 +17.4% 106.26 US$3,354,628
2023-08-11 2023-08-10 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
1,091 +0.6%
105.90
US$115,537 		1,091 +0.6% 105.90 US$115,537
2023-08-11 2023-08-10 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
2,206 +1.2%
104.67
US$230,902 		2,206 +1.2% 104.67 US$230,902
2023-08-08 2023-08-04 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
15,000 -41.7%
106.72
US$1,600,800 		15,000 -41.7% 106.72 US$1,600,800
2023-08-04 2023-08-04 PrS Proposed sale
3.6
Wigzell Hans Lennart Rudolf

Director

Non-Executive Director
15,000
106.00
US$1,590,000 		15,000 106.00 US$1,590,000
2022-11-21 2022-11-17 S Sale
2.2
Mayo Stephen
Non-Executive Director
858 -11.8%
109.92
US$94,311 		858 -11.8% 109.92 US$94,311
2022-09-15 2022-09-14 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
6,250 +6.1%
105.16
US$657,250 		6,250 +6.1% 105.16 US$657,250
2022-09-15 2022-09-14 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
30,106 +41.9%
104.67
US$3,151,195 		30,106 +41.9% 104.67 US$3,151,195
2022-09-15 2022-09-14 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
20,744 +40.6%
103.87
US$2,154,679 		20,744 +40.6% 103.87 US$2,154,679
2022-08-22 2022-08-19 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
6,060 +13.5%
108.80
US$659,328 		6,060 +13.5% 108.80 US$659,328
2022-08-22 2022-08-19 B Purchase
2.9
Chambers Michael Andrew
Non-Executive Director
40,110 +817.2%
108.20
US$4,339,902 		40,110 +817.2% 108.20 US$4,339,902
2021-11-29 2021-11-24 B Purchase
2.3
Rodino-Klapac Louise

Head of R&D, CSO

Officer
3,780 +6.1%
79.33
US$299,867 		3,780 +6.1% 79.33 US$299,867
2021-11-17 2021-11-17 B Purchase
3.5
INGRAM DOUGLAS S

President & CEO

Executive Director
25,026 +7.4%
79.94
US$2,000,578 		25,026 +7.4% 79.94 US$2,000,578
2021-03-10 2021-03-10 S Sale
2.1
BEHRENS M KATHLEEN
Non-Executive Director
5,000 -3.7%
85.76
US$428,800 		5,000 -3.7% 85.76 US$428,800
2021-03-10 2021-03-08 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
10,000 -37.7%
83.51
US$835,100 		10,000 -37.7% 83.51 US$835,100
2020-12-14 2020-12-11 PlS Planned sale
Bratica Joseph

Principal Financial Officer

Officer
1,115 -12.0%
165.00
US$183,975 		1,115 -12.0% 165.00 US$183,975
2020-12-10 2020-12-08 PlS Planned sale
Bratica Joseph

Principal Financial Officer

Officer
1,125 -12.1%
160.00
US$180,000 		1,125 -12.1% 160.00 US$180,000
2020-08-11 2020-08-10 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
777 -5.3%
159.65
US$124,048 		777 -5.3% 159.65 US$124,048
2020-08-11 2020-08-10 S Sale
3.6
Wigzell Hans Lennart Rudolf
Non-Executive Director
9,223 -38.8%
158.95
US$1,465,996 		9,223 -38.8% 158.95 US$1,465,996
Explore more

More insider trading research around Sarepta Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America